Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening.


Journal

Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260

Informations de publication

Date de publication:
11 2020
Historique:
pubmed: 9 9 2020
medline: 29 12 2020
entrez: 8 9 2020
Statut: ppublish

Résumé

Background Mammography screening reduces breast cancer mortality, but a proportion of breast cancers are missed and are detected at later stages or develop during between-screening intervals. Purpose To develop a risk model based on negative mammograms that identifies women likely to be diagnosed with breast cancer before or at the next screening examination. Materials and Methods This study was based on the prospective screening cohort Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA), 2011-2017. An image-based risk model was developed by using the Stratus method and computer-aided detection mammographic features (density, masses, microcalcifications), differences in the left and right breasts, and age. The lifestyle extended model included menopausal status, family history of breast cancer, body mass index, hormone replacement therapy, and use of tobacco and alcohol. The genetic extended model included a polygenic risk score with 313 single nucleotide polymorphisms. Age-adjusted relative risks and tumor subtype specific risks were estimated by using logistic regression, and absolute risks were calculated. Results Of 70 877 participants in the KARMA cohort, 974 incident cancers were sampled from 9376 healthy women (mean age, 54 years ± 10 [standard deviation]). The area under the receiver operating characteristic curve (AUC) for the image-based model was 0.73 (95% confidence interval [CI]: 0.71, 0.74). The AUCs for the lifestyle and genetic extended models were 0.74 (95% CI: 0.72, 0.75) and 0.77 (95% CI: 0.75, 0.79), respectively. There was a relative eightfold difference in risk between women at high risk and those at general risk. High-risk women were more likely to be diagnosed with stage II cancers and with tumors 20 mm or larger and were less likely to have stage I and estrogen receptor-positive tumors. The image-based model was validated in three external cohorts. Conclusion By combining three mammographic features, differences in the left and right breasts, and optionally lifestyle factors and family history and a polygenic risk score, the model identified women at high likelihood of being diagnosed with breast cancer within 2 years of a negative screening examination and in possible need of supplemental screening. © RSNA, 2020

Identifiants

pubmed: 32897160
doi: 10.1148/radiol.2020201620
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

327-333

Auteurs

Mikael Eriksson (M)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Kamila Czene (K)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Fredrik Strand (F)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Sophia Zackrisson (S)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Peter Lindholm (P)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Kristina Lång (K)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Daniel Förnvik (D)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Hanna Sartor (H)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Nasim Mavaddat (N)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Doug Easton (D)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Per Hall (P)

From the Department of Medical Epidemiology and Biostatistics (M.E., K.C., P.H.) and Department of Oncology-Pathology (F.S.), Karolinska Institutet, Nobelsv 12A, Stockholm 171 77, Sweden; Department of Breast Radiology, Karolinska University Hospital, Stockholm, Sweden (F.S.); Department of Diagnostic Radiology, Lund University, Skåne University Hospital Malmö, Sweden (S.Z., K.L., D.F., H.S.); Department of Thoracic Radiology, Imaging and Physiology and Department of Physiology and Pharmacology, Karolinska Hospital, Stockholm, Sweden (P.L.); Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care (N.M., D.E.) and Department of Oncology (D.E.), University of Cambridge, Cambridge, England; and Department of Oncology, Södersjukhuset, Stockholm, Sweden (P.H.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH